Professor Jiang Zefei: Looking back and looking forward to comprehensively promoting a new model of breast cancer diagnosis and treatment in multiple fields and new situations

"Breast Cancer Treatment Annual Progress Review and 2022 CSCO BC Guidelines Update Seminar" will be held on January 8, 2022
.

This conference focuses on important developments in the field of international and domestic breast cancer in 2021, and invites well-known experts and scholars in the field of breast cancer to give keynote speeches on translational research, surgical treatment, radiotherapy, early breast cancer and advanced breast cancer treatment.
Review and summarize the important research results that have changed the clinical practice of breast cancer
.

At the same time, feedback on the 2021 CSCO BC diagnosis and treatment guidelines will be discussed, and the update of the 2022 version of the CSCO BC guidelines will be initiated
.

Yimaitong invited the chairman of the conference and Professor Jiang Zefei from the Department of Oncology, General Hospital of the People's Liberation Army to share the highlights of this conference
.

Expert Profile Professor Jiang Zefei Chief Physician, Professor, and Doctoral Supervisor Deputy Director, Department of Oncology, PLA General Hospital, Vice Chairman and Secretary-General, Chinese Society of Clinical Oncology (CSCO), Vice-President and Secretary-General, Chinese Society of Anti-Cancer Association (CACA) Breast Cancer Professional Committee, Designated Chairman, Chinese Clinical Oncology The Chairman of the Society of Breast Cancer Expert Committee (CSCO BC), the consultant of the Breast Oncology Group of the Oncology Branch of the Chinese Medical Association, St.
Gallen Breast Cancer Conference, the international expert group online meeting as scheduled, to promote the overall development of the breast cancer field Professor Jiang Zefei once a year The annual review meeting of breast cancer treatment progress is coming as scheduled.
We invite industry experts to review and discuss the academic progress of this year in the field of breast cancer at home and abroad in January each year, and start the update of the guidelines based on the results of the annual review
.

This year, in accordance with the requirements of epidemic prevention and control, experts will jointly participate in the online live broadcast to conduct a systematic review of the progress of surgery, internal medicine, radiotherapy, pathology, international progress, domestic development and other aspects and discuss the update of the guidelines
.

In addition, we also invited a number of domestic young and middle-aged experts to focus on the feedback after the CSCO BC guidelines were issued, as well as important developments that may change clinical practice or guidelines in various areas of breast cancer, such as new clinical research results, new Related information such as product access and new medical insurance approval for your reference
.

Annual review of research progress, influence on breast cancer clinical practice decision-making Professor Jiang Zefei In the past year, the progress of breast cancer research continues to be good news
.

In the field of HER2-positive breast cancer, in addition to antibody drugs, research on tyrosine kinase inhibitors (TKI) and antibody-drug conjugates (ADC) has made key progress at home and abroad, such as the first in second-line treatment The head-to-head comparison of T-DXd and T-DM1 in the international multi-center phase III clinical trial DESTINY-Breast 03 study is expected to rewrite the practice guidelines for advanced HER2-positive breast cancer, establish new treatment standards, and a series of studies related to T-DXd It is in full swing
.

There are also many ADC drugs in China that have made breakthroughs in the field of breast cancer
.

Therefore, in the field of HER2-positive breast cancer, the preoperative, postoperative, and recurrence and metastasis treatment models will continue to be updated
.

For hormone receptor-positive breast cancer patients, there are more options for combined treatment
.

For example, CDK4/6 inhibitors have not only updated the mid-term and long-term follow-up results of international multi-center clinical studies this year, but also the research results of domestic independent research and development products have been published in internationally renowned journals, and they have been or will be approved
.

It is foreseeable that more drugs will be available in time in the future, which will be more conducive to patients' treatment options
.

For patients with triple-negative breast cancer, chemotherapy has been the mainstay in the past
.

In the past year, immunotherapy and targeted therapy have also made great progress in the field of advanced triple-negative breast cancer
.

At the same time, we also hope that the CSCO breast cancer guidelines can help clinicians make scientific and reasonable treatment decisions
.

Of course, with the development of technology, the Internet and artificial intelligence, intelligent systems continue to improve.
This year’s CSCO breast cancer guide may incorporate elements such as artificial intelligence and case management.
At the same time, under the normalization of epidemic prevention and control, disease management and breast cancer patient vaccines Expert consensus on vaccination will also be included in the guidelines
.

I believe that after this annual review meeting, we will draw on evidence-based medicine evidence, combine the clinical experience of Chinese experts, and fully consider the availability of Chinese clinical practice to formulate a more realistic CSCO breast cancer diagnosis and treatment guideline that is in line with Chinese clinical practice.

.

The CSCO breast cancer guidelines are updated, and the new approach is to promote the best solution for diagnosis and treatment.
Professor Jiang Zefei.
In 2017, the CSCO Breast Cancer Special Committee issued the first edition of the CSCO Breast Cancer Diagnosis and Treatment Guidelines, which are based on evidence-based medical evidence and take into account the accessibility of diagnosis and treatment plans.
The updated guidelines have been widely welcomed and affirmed by the industry.
The annual circulation is about 80,000 to 100,000 copies, which can be said to be one manual
.

At the same time, in order to help readers better understand the updated points of the guidelines, the CSCO Breast Cancer Special Committee will organize a guide tour, inviting well-known experts in the field of breast cancer to interpret and discuss the guidelines, and receive a lot of valuable feedback in the promotion and application.
Opinion
.

With the development of artificial intelligence, we will abandon the original model of issuing a paper version of the guide and then integrating it into the smart version.
Instead, we will adopt a model where the smart version has priority over the paper version
.

In the future, the guide may be updated at any time like smart navigation
.

After moving toward intelligence and interconnection, high-tech and new models will allow more scholars to open such a diagnosis and treatment "navigation" system very conveniently, combining the availability of medicines and the proportion of medical insurance reimbursement, so that doctors can accurately control the diagnosis and treatment of patients.
The optimal path brings the greatest benefit to patients
.

First look at the meeting schedule